RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $323 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $323 price target.
June 22, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating on Vertex Pharmaceuticals and maintained a $323 price target.
The news of RBC Capital reiterating a Sector Perform rating and maintaining a $323 price target on Vertex Pharmaceuticals is neutral for the stock. It indicates that the analyst believes the stock is fairly valued and is expected to perform in line with the sector. This news does not provide any new information or catalyst for the stock to move significantly in either direction.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100